These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 30690043)

  • 1. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
    Piret J; Boivin G
    Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonistic Relationship between Human Cytomegalovirus pUL27 and pUL97 Activities during Infection.
    Bigley TM; Reitsma JM; Terhune SS
    J Virol; 2015 Oct; 89(20):10230-46. PubMed ID: 26223645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus.
    O'Brien MS; Markovich KC; Selleseth D; DeVita AV; Sethna P; Gentry BG
    Antiviral Res; 2018 Oct; 158():255-263. PubMed ID: 30153445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure.
    Muller C; Tilloy V; Frobert E; Feghoul L; Garrigue I; Lepiller Q; Mirand A; Sidorov E; Hantz S; Alain S
    Antiviral Res; 2022 Aug; 204():105361. PubMed ID: 35690130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological and clinical effects of letermovir (Prevymis
    Ogawa M; Eto T
    Nihon Yakurigaku Zasshi; 2019; 153(4):192-198. PubMed ID: 30971660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir.
    Piret J; Boivin G
    Infect Dis Rep; 2024 Jan; 16(1):65-82. PubMed ID: 38247977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products.
    Komatsu TE; Hodowanec AC; Colberg-Poley AM; Pikis A; Singer ME; O'Rear JJ; Donaldson EF
    Antiviral Res; 2019 Sep; 169():104549. PubMed ID: 31279814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery and development of filociclovir for the prevention and treatment of human cytomegalovirus-related disease.
    Hussein ITM; Brooks J; Bowlin TL
    Antiviral Res; 2020 Apr; 176():104710. PubMed ID: 31940473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cellular STAT3 synergizes with the cytomegalovirus kinase inhibitor maribavir to disrupt infection.
    Reitsma JM; Terhune SS
    Antiviral Res; 2013 Nov; 100(2):321-7. PubMed ID: 24070820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection.
    Hakki M; Drummond C; Houser B; Marousek G; Chou S
    Antiviral Res; 2011 Nov; 92(2):313-8. PubMed ID: 21906628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the terminase: An important step forward in the treatment and prophylaxis of human cytomegalovirus infections.
    Gentry BG; Bogner E; Drach JC
    Antiviral Res; 2019 Jan; 161():116-124. PubMed ID: 30472161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients.
    Razonable RR
    Drug Des Devel Ther; 2024; 18():3987-4001. PubMed ID: 39258274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
    Chou S
    Antimicrob Agents Chemother; 2009 Jan; 53(1):81-5. PubMed ID: 18981262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient.
    Schubert A; Ehlert K; Schuler-Luettmann S; Gentner E; Mertens T; Michel D
    BMC Infect Dis; 2013 Jul; 13():330. PubMed ID: 23870704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility.
    Webel R; Hakki M; Prichard MN; Rawlinson WD; Marschall M; Chou S
    J Virol; 2014 May; 88(9):4776-85. PubMed ID: 24522923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes.
    Piret J; Goyette N; Boivin G
    Antiviral Res; 2022 Jun; 202():105328. PubMed ID: 35490740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27.
    Komazin G; Ptak RG; Emmer BT; Townsend LB; Drach JC
    J Virol; 2003 Nov; 77(21):11499-506. PubMed ID: 14557635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placental transfer of Letermovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection.
    Faure Bardon V; Peytavin G; Lê MP; Guilleminot T; Elefant E; Stirnemann J; Leruez-Ville M; Ville Y
    PLoS One; 2020; 15(4):e0232140. PubMed ID: 32353010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by
    Chou S; Satterwhite LE; Ercolani RJ
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.